PubRank

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Clinical Trial ID NCT02224781

PubWeight™ 19.27‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02224781

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015 2.25
2 Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 2015 1.54
3 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
4 Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015 1.06
5 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
6 Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015 0.98
7 Updates in Therapy for Advanced Melanoma. Cancers (Basel) 2016 0.91
8 Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med 2016 0.90
9 New strategies in immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2015 0.89
10 Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol 2016 0.87
11 Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer 2016 0.84
12 Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma. Onco Targets Ther 2016 0.82
13 Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol 2015 0.82
14 Clinical utility of nivolumab in the treatment of advanced melanoma. Ther Clin Risk Manag 2016 0.81
15 Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). Int J Radiat Oncol Biol Phys 2016 0.80
16 Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs 2016 0.80
17 Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biol Ther 2015 0.79
18 The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. Dermatol Ther (Heidelb) 2015 0.78
19 CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux. Clin Cancer Res 2015 0.75
20 The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol 2016 0.75
21 Dabrafenib in metastatic melanoma: a monocentric 'real life' experience. Ecancermedicalscience 2016 0.75
Next 100